Sulphonylureas, which are widely used in the treatment of Type II (non-insulin-dependent) diabetes mellitus, stimulate insulin secretion from pancreatic beta-cells by inhibiting ATP-sensitive K-channels (K ATP channels). Members of the K ATP channel family are found in a variety of other tissues, including cardiac, skeletal and smooth muscle and neurones, where they couple the metabolic state of a cell to its electrical activity. In beta-cells, the activity of K ATP channels is modulated by cell metabolism and regulates the membrane potential. Closure of the K ATP channels in response to glucose results in membrane depolarisation. This opens voltage-gated Ca 2+ channels, allowing calcium influx and thereby triggering insulin release [1] .
beta-cell K ATP channels at two sites: a high-affinity site, which is half-maximally blocked (K i ) at 50 7 nmol/l (n = 8) and a low-affinity site with a K i of 3.0 0.6 mmol/l (n = 4). The high-affinity site on SUR1 was thus about 40-fold more sensitive to gliclazide than to tolbutamide (K i~2 mmol/l). Cloned cardiac and smooth muscle K ATP channels did not show high-affinity block by gliclazide. Kir6.2-SUR2A currents exhibited a single low-affinity site with a K i of 0.8 0.1 mmol/l (n = 5), which is likely to reside on the Kir6.2 subunit. Conclusion/interpretation. Our results show that gliclazide is a sulphonylurea with high affinity and strong selectivity for the beta-cell type of K ATP channel.
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with high affinity but has relatively little effect on cardiac channels. Glibenclamide, however, is less tissue specific, blocking both beta-cell and cardiac K ATP channels [7, 8] . In this paper we have investigated the selectivity of gliclazide, a widely used second generation sulphonylurea, for beta-cell, cardiac and smooth muscle K ATP channels.
Materials and methods
Molecular biology. Mouse Kir6.2 (Genbank D50581; [3] ), rat SUR1 (Genbank L40624; [2] ), SUR2A (Genbank D83598; [5] ) and SUR2B (Genbank D86038; [6] ) cDNAs were cloned in the pBF vector. A truncated form of Kir6.2 (Kir6.2DC36), which lacks the C-terminal 36 amino acids and forms functional channels in the absence of SUR, was prepared as described previously [4] . Capped mRNA was prepared using the mMessage mMachine large scale in vitro transcription kit (Ambion, Austin, Tex., USA).
Oocyte collection. Oocytes were collected by mini-laparotomy from female Xenopus laevis anaesthetised with MS222 (2 g/l added to the water). Immature stage V-VI oocytes were incubated for 60 min with 1.0 mg/ml collagenase (Sigma, type V, Poole, UK) and manually defolliculated. Oocytes were either injected with approximately 1 ng Kir6.2DC36 mRNA or coinjected with approximately 0.1 ng Kir6.2 mRNA and approximately 2 ng of mRNA encoding one of the types of SUR. The final injection volume was 50 nl/oocyte. Isolated oocytes were maintained in Barth's solution and studied 1±4 days after injection [9] .
Electrophysiology. Patch pipettes were pulled from thick-walled borosilicate glass and had resistances of 250±500 kW when filled with pipette solution. Macroscopic currents were recorded from giant excised inside-out patches at a holding potential of 0 mV and at 20±24°C [9] . Currents were evoked by repetitive 3-s voltage ramps from ±110 mV to + 100 mV and recorded using an EPC7 patch-clamp amplifier (List Electronik, Darmstadt, Germany). They were filtered at 0.2 kHz, digitised at 0.4 kHz using a Digidata 1200 Interface and analysed using pClamp software (Axon Instruments, Burlingame, USA). Records were stored on video tape and resampled at 20 Hz for presentation in the figures.
The pipette (external) solution contained (mmol/l): 140 KCl, 1. was approximately 140 mmol/l after addition of gliclazide. Rapid exchange of solutions was achieved by positioning the patch in the mouth of one of a series of adjacent inflow pipes placed in the bath. Test solutions were applied in random order, and patches were exposed to 1 mmol/l MgATP at intervals throughout the experiment, to reverse channel rundown.
Data analysis. The slope conductance was measured by fitting a straight line to the current-voltage relation between ±20 mV and ±100 mV; the average of five consecutive ramps was calculated in each solution. Data are presented as means ± 1 SEM.
Dose-response curves were fit to the following equation (eq.) [9] :
where G is the conductance in the presence of gliclazide, G c is the conductance in control solution, x is a term describing the high-affinity site and y a term describing the low-affinity site.
where [Glic] is the gliclazide concentration, K i1 , K i2 are the gliclazide concentrations at which inhibition is half maximum at high-and low-affinity sites, respectively; h1, h2 are the Hill coefficients (slope factors) for the high-and low-affinity sites, respectively; and L is the fractional conductance remaining when the high-affinity sites are fully occupied. When only a single site is present, the equation reduces to G/G c = x (eq. 4). To control for the rundown of channel activity that occurs in excised patches, dose-response curves were constructed by expressing the conductance in the presence of gliclazide as a fraction of the mean of the conductances measured in control solution before and after addition of the drug.
Results
Macroscopic currents were recorded in inside-out membrane patches from Xenopus oocytes coexpressing Kir6.2 and either SUR1, SUR2A or SUR2B. In all cases, the currents were small in the cell-attached configuration but increased considerably when the patch was excised into nucleotide-free solution. This is consistent with the idea that the K ATP channel is blocked in the intact oocyte by cytoplasmic nucleotides such as ATP. The application of 10 mmol/l gliclazide to the intracellular membrane surface reversibly blocked Kir6.2-SUR1 currents by 61 4 % (n = 8), but had little effect on either Kir6.2-SUR2A currents (6 3 % block, n = 6) or Kir6.2-SUR2B currents (8 2 % block, n = 5) (Fig. 1A) .
We reported previously that tolbutamide inhibits beta-cell K ATP channels at two sites: a high-affinity site, conferred by SUR1 and a low-affinity site on Kir6.2 [9] . The high-affinity site has a K i of approximately 2 mmol/l and, when fully saturated by 100 mmol/l tolbutamide, the current amplitude is reduced by about 50 %. Kir6.2-SUR2A currents show only low-affinity tolbutamide inhibition [8] . We therefore measured the relation between the gliclazide concentration and the K ATP current for both Kir6.2-SUR1 and Kir6.2-SUR2A channels (Fig. 1Bi) . As with tolbutamide, the inhibition of Kir6.2-SUR1 currents by gliclazide showed both high-and low-affinity sites with K i s of 50 7 nmol/l (n = 8) and 3.0 0.6 mmol/l (n = 4), respectively. Kir6.2-SUR2A currents, in contrast, showed only low-affinity inhibition by gliclazide, with a K i of 0.8 0.1 mmol/l (n = 5).
Low-affinity inhibition of Kir6.2-SUR1 and Kir6.2-SUR2A channels by sulphonylureas has also been reported for tolbutamide. This site is not conferred by the sulphonylurea receptor, since it is also observed when truncated Kir6.2 subunits (Kir6.2DC36) are expressed in the absence of SUR [8, 9] . To investigate whether the low-affinity site for gliclazide is also independent of SUR, we tested the effect of the drug on Kir6.2DC36 channels. Gliclazide blocked Kir6.2DC36 currents at low affinity, with a K i of 2.7 0.3 mmol/l (n = 5), suggesting that the low-affinity gliclazide site lies on Kir6.2 itself (Fig. 1Bii) .
Discussion
Our results show that gliclazide blocks K ATP channels from beta-cells but not those from cardiac or smooth muscle, with high affinity. This high-affinity sulphonylurea site, located on SUR1, is about 40-fold more sensitive to gliclazide than to tolbutamide. A low-affinity site for gliclazide was observed for Kir6.2-SUR1, Kir6.2-SUR2A and Kir6.2DC36 currents and is likely to reside on the Kir6.2 subunit.
The responses of beta-cell and cardiac K ATP currents to gliclazide are qualitatively similar to those previously observed with tolbutamide, which blocked Kir6.2-SUR1 currents at high-affinity and low-affinity sites (K i s of~2 mmol/l and~2 mmol/l, respectively) and Kir6.2-SUR2A currents at a single low-affinity site (K i~2 mmol/l; [8] ). The principal difference between the two drugs, therefore, is the greater sensitivity of the high-affinity site on SUR1 to gliclazide (K i~5 0 nmol/l) than to tolbutamide (K i~2 mmol/l). Since the only structural difference between these drugs is the substitution of an azobicyclo ring in the gliclazide molecule (Fig. 2) , this group is likely to be involved in high-affinity binding to SUR1.
Glibenclamide (Fig. 2 ) also exhibits high-affinity binding to SUR1 (K i~4 nmol/l; [2, 8] ), but its inhibitory effect on K ATP currents differs in two important respects from that observed with gliclazide. Firstly, the block of Kir6.2-SUR1 currents by glibenclamide is effectively irreversible, whereas that of gliclazide reverses rapidly. Secondly, glibenclamide, but not gliclazide, blocks the cardiac type of K ATP channel with high affinity. We suggested previously that the non-sulphonylurea moiety of glibenclamide is responsible both for its effectiveness on cardiac K ATP channels and for the irreversibility of its action on the beta-cell K ATP channel. The data presented here suggest that the ring on the sulphonylurea tail of glibenclamide may contribute to the high affinity of the drug.
Gliclazide and tolbutamide blocked Kir6.2DC36 currents with similar K i s (~2 mmol/l and~3 mmol/ l, respectively), suggesting that the low-affinity site on Kir6.2 is not sensitive to the structural differences between the two drugs.
Our results suggest that therapeutic concentrations of gliclazide (1±25 mmol/l; [10] ) should selectively block beta-cell K ATP channels and produce little cross-reactivity with cardiac and smooth muscle K ATP channels. The clinical importance of the extrapancreatic actions of sulphonylureas remains controversial, since both beneficial and harmful side effects have been reported in the literature. It is clear that the sulphonylureas should not be considered as a homogeneous group when looking for possible side effects, since only some of the drugs interact with K ATP channels in extrapancreatic tissues. Understanding the tissue specificity of individual sulphonylureas is therefore a crucial step in planning further studies in this area.
